[{"StockholdersEquityConverted_0_Q2_USD":-457490000.0,"NetCashProvidedByUsedInOperatingActivitiesConverted_2_Q2_USD":-242478000.0,"CommonStockSharesOutstanding_0_Q2_shares":149614740.0,"StockholdersEquity_0_Q2_USD":-464294000.0,"EarningsPerShareBasic_1_Q2_USD":-0.66,"EarningsPerShareBasic_2_Q2_USD":-1.82,"RevenuesConverted_1_Q2_USD":54024000.0,"RevenuesConverted_2_Q2_USD":54486000.0,"Assets_0_Q2_USD":1081486000.0,"CommonStockSharesConverted_0_Q2_shares":152894108.0,"NetIncomeLossConverted_1_Q2_USD":-96348000.0,"NetIncomeLossConverted_2_Q2_USD":-259427000.0,"Ticker":"BBIO","CIK":"1743881","name":"BRIDGEBIO PHARMA, INC.","OfficialName":"BridgeBio Pharma Inc. Common Stock","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1594164456.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210805"}]